Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 106 of 6351
-
New obesity drug aims for major weight loss in phase 3 trial
Disease control CompletedA multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus
Phase 3 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control Recruiting nowThis is a multi-center, Phase 1/2/3, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of BBM-H803 injection in severe Hemophilia A subjects. BBM-H803 is an adeno-associated viral (AAV) vector derived from recombinant …
Phase 2/3 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Double strike: engineered immune cells and targeted pill take on tough leukemia
Disease control Recruiting nowThis is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.
Early phase 1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Artificial intelligence may detect Children's heart disease from a routine ECG
Diagnosis CancelledCongenital heart disease (CHD) is the most common congenital disease in children. The early detection, diagnosis and treatment of CHD in children is of great significance to improve the prognosis and reduce the mortality of children, but the current screening methods have limitat…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Shorter TB treatment: a 4-Month regimen put to the test
Disease control Recruiting nowTuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030. With the concerted efforts of the government and medical community, the incidence of TB in Taiwan has gradually decreased, however, Taiwan remains an e…
Phase 3 • Sponsor: Kaohsiung Veterans General Hospital. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Smart wearables and blood markers could spot Parkinson's years before symptoms worsen
Diagnosis Recruiting nowBased on the high-quality Parkinson's disease cohort population and biological sample database in the early stage of the team, multi-dimensional intelligent wearable device technology and machine learning were used to screen and classify digital biomarkers in the prodromal PD coh…
Sponsor: Fujian Medical University Union Hospital • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: drug targets even low HER2 levels
Disease control Recruiting nowThis study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or met…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to make stem cell transplants safer for sickle cell patients
Disease control OngoingBackground: Sickle cell disease (SCD) is a genetic disorder where red blood cells, that carry oxygen, are stiff and become stuck in small blood vessels. As a result, affected patients can experience severe pain and serious organ damage. SCD can be cured with a hematopoietic cell…
Phase 1/2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New CAR T-Cell therapy aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Double-Pronged attack: new CAR T-Cell therapy targets Hard-to-Treat myeloma
Disease control Recruiting nowThis study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Phase 1/2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control OngoingThis Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in Japanese patients with severe hemophilia A.
Phase 3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for KRAS lung cancer: major trial launches for targeted combo therapy
Disease control Recruiting nowThe purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study partici…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New lung cancer pill could beat current standard in ROS1-Positive patients
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowRESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Phase 2/3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug could prevent Life-Threatening fetal anemia in High-Risk pregnancies
Disease control Recruiting nowThe purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in p…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
One shot for two threats: combined COVID-Flu vaccine moves to final testing
Vaccine CompletedThe purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily f…
Phase 3 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 08:01 UTC
-
New pill targets bile duct cancer that resists standard treatments
Disease control OngoingThis study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed C…
Phase 3 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a DNA vaccine boost immunotherapy against HPV-Linked head and neck cancer?
Disease control Recruiting nowThis is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC). The trial is designed to investigate VB10.16, an investigational therapeutic DNA vaccine in combination with another med…
Phase 1/2 • Sponsor: Nykode Therapeutics ASA • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat breast cancer spread to brain
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in combination with intrathecal trastuzumab on overall survival rate at 12 months in HER2-positive metastatic breast cancer (MBC) patients with proven leptomeningeal evolution and requiring …
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise for rare lung cancer mutation
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Phase 3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC